However, Merck announced in December 2024 it was licensing Hansoh Pharma's obesity drug HS-10535. This move added a new (and potentially formidable) competitor for Viking and greatly reduced the ...
However, Merck announced in December 2024 it was licensing Hansoh Pharma's obesity drug HS-10535. This move added a new (and potentially formidable) competitor for Viking and greatly reduced the ...
Also, Viking was seen by some as a potential acquisition target for Merck. However, Merck announced in December 2024 it was licensing Hansoh Pharma's obesity drug HS-10535. This move added a new (and ...
U.S. company Merck (MSD) signed an exclusive license agreement for the obesity treatment 'HS-10535' with Chinese pharmaceutical corporation Hansoh Pharmaceuticals last December. This is a large ...
Merck & Co. signed an exclusive global license agreement with Chinese pharmaceutical company Hansoh Pharma for HS-10535, an oral glucagon-like peptide-1 (GLP-1) receptor agonist being developed as ...
The company has penned a deal to develop a potential GLP-1 weight loss therapy, HS-10535, with China-based Hansoh Pharma. It signed a similar licensing deal with LaNova Medicines for the ...